CagriSema REDEFINE-1: what the 20.4% weight-loss number actually means.

The headline number on Novo Nordisk’s CagriSema is 20.4% mean weight loss at 68 weeks. That’s the largest sustained pharmaceutical weight-loss number ever published. The trial behind it (REDEFINE-1) is more interesting than the headline.

Obesity affects roughly 42% of US adults. The downstream cost (type 2 diabetes, sleep apnea, fatty liver, cardiovascular disease) is what makes every GLP-1 readout the most-watched event in metabolic medicine.

Semaglutide (Wegovy) and tirzepatide (Zepbound) are already FDA-approved. They produce 15–22% weight loss in their own pivotal trials. The question REDEFINE-1 was built to answer: does stacking a second mechanism on top of GLP-1 unlock a higher ceiling, or just add side effects?

Here’s how the trial was designed, what the four arms actually showed, and what to make of the GI rate the press releases gloss over.

Why combine cagrilintide with semaglutide?

Cagrilintide and semaglutide work on different parts of the satiety circuit.

Semaglutide is a GLP-1 (a gut hormone that signals fullness) receptor agonist. It slows stomach emptying, increases glucose-dependent insulin release, and signals satiety through the hindbrain.

Cagrilintide is a long-acting copy of amylin, a hormone the pancreas releases alongside insulin when you eat. Amylin works through different receptors and slows stomach emptying through a parallel pathway. It also suppresses glucagon at meal times.

A 2024 review by Melson at the University of Leicester describes the rationale. Amylin and GLP-1 act through partially overlapping but distinct circuits. Stacking them recruits both, which is why combination drugs in this class (CagriSema, retatrutide, mazdutide, survodutide) consistently outperform pure GLP-1.

Cagrilintide itself wasn’t a random pick. Natural amylin has a very short half-life and forms toxic protein clumps, the same clumps implicated in type 2 diabetes pathology. Novo Nordisk’s contribution was engineering a long-acting, non-clumping version suitable for once-weekly injection. That’s what made CagriSema practical.

Cagrilintide

Amylin analog 37 aa Long-acting

The same compound studied in the REDEFINE Phase III trials. Lab-verified identity and purity.

View Cagrilintide

What did REDEFINE-1 actually find?

REDEFINE-1 was led by W. Timothy Garvey at the University of Alabama at Birmingham. The trial was Phase 3a, 68 weeks, double-blind, placebo-controlled and active-controlled.

The team randomized 3,417 adults with overweight or obesity (without diabetes) into four arms: CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg), semaglutide alone, cagrilintide alone, or placebo. All arms got lifestyle intervention.

The headline result: 20.4% mean weight loss in the CagriSema arm at week 68, vs 3.0% placebo. Treatment difference: −17.3 percentage points (95% CI −18.1 to −16.6, P<0.001).

That’s the largest pharmaceutical weight-loss number on the books. It puts CagriSema in the conversation with sleeve gastrectomy in the medium term.

The threshold-response numbers are arguably more useful than the mean. The trial reported significantly more participants reaching ≥5%, ≥20%, ≥25%, and ≥30% weight-loss thresholds on CagriSema than placebo.

Threshold response is what predicts whether comorbidities reverse. Once you cross 15%, the evidence base for diabetes remission and sleep-apnea reversal becomes meaningful.

What about the type 2 diabetes population?

REDEFINE-2 ran in parallel. Davies published the companion trial in 1,206 adults with type 2 diabetes and BMI ≥27, randomized 3:1 to CagriSema vs placebo over the same 68-week window.

Weight loss in the diabetic cohort came in lower than the non-diabetic cohort: 13.7% with CagriSema vs 3.4% with placebo. That’s the expected pattern across this drug class. Study participants with diabetes have consistently shown less weight reduction than non-diabetic participants on incretin therapy across this compound class. Background medications and the metabolic features of diabetes both contribute.

The glucose numbers are where REDEFINE-2 really earns attention. 73.5% of CagriSema participants hit an HbA1c ≤6.5% (the diabetes-remission threshold) vs just 15.9% on placebo. That’s a four-fold rate difference on the most-cited diabetes-control endpoint. The kind of result that reshapes treatment algorithms.

How tolerable is it really?

This is what the press releases under-cover. GI side effects hit 79.6% of CagriSema participants in REDEFINE-1 vs 39.9% on placebo. About double.

The events are mostly mild-to-moderate and largely transient: nausea, vomiting, diarrhea, constipation, abdominal pain. They’re consistent with the broader GLP-1 class’s tolerability profile, not unique to this combination.

A 2024 meta-analysis by Dutta aggregated the cagrilintide and CagriSema RCT data through 2024 and found something interesting. Cagrilintide alone produced weight loss comparable to semaglutide and liraglutide, but with significantly less vomiting. That suggests the amylin component itself is better tolerated than GLP-1, and the high GI rate in CagriSema is largely driven by the semaglutide piece.

Regulatory context and research implications

CagriSema was not FDA-approved as of mid-2026. Novo Nordisk’s submission was anticipated following the REDEFINE readouts. Approval timelines for this class have typically run 12–18 months from submission.

REDEFINE-1 was designed as an active-controlled trial — comparing CagriSema not only against placebo but against semaglutide monotherapy. This design choice is significant for interpreting the literature: it allows the incremental contribution of cagrilintide to be isolated from the GLP-1 effect.

• Comparative magnitude: Semaglutide and tirzepatide monotherapy trials reported roughly 15% and 22% weight loss in their own pivotal cohorts. REDEFINE-1’s 20.4% combination result was competitive with tirzepatide’s upper range.
• Responder heterogeneity: The threshold-response data demonstrated wide individual variation, with a subpopulation reaching ≥30% weight loss. Early study weeks (12–16) have been proposed as a predictive window for response classification.
• GI tolerability profile: The 79.6% GI adverse-event rate was largely driven by the semaglutide component, consistent with Dutta et al.’s finding that cagrilintide monotherapy produced significantly less vomiting than GLP-1 agonists.
• Cardiovascular and gallbladder signals: Pancreatitis and gallbladder adverse events are class effects of incretin therapy that have been tracked across incretin trials.
• Compound identity considerations: Cagrilintide is a 37-amino-acid acylated peptide. Synthesis is technically demanding; the Novo Nordisk fixed-dose combination formulation differs from individually sourced components, and characterization of separately procured materials varies.

Cagrilintide

10 mg ≥99% pure Lyophilized

Long-acting acylated amylin analog · 37 aa. The same compound studied in the REDEFINE Phase III trials. COA available with each lot.

Learn more

How does this compare to bariatric surgery?

This is the comparison every metabolic clinician is now making. Sleeve gastrectomy produces roughly 25–30% sustained weight loss at one year. Roux-en-Y bypass produces 30–35%. CagriSema’s 20.4% at 68 weeks closes more of that gap than any prior pharmaceutical. It doesn’t close it entirely, and durability past 68 weeks remains unknown.